Substantia nigra hyperechogenicity in Polish patients with Parkinson’s disease

• Autorzy: Ambrosius W. , Michalak S. , Owecki M. , Lukasik M. , Florczak-Wyspianska J. , Kozubski W.
• Języki publikacji: EN

Abstrakty

EN

Background: Hyperechogenicity of the substantia nigra (SN) measured by transcranial sonography (TCS) is a characteristic feature observed in patients with Parkinson’s disease (PD). To our knowledge, no SN hyperechogenicity data are available for Polish population. Moreover most of studies come from few centres, which used the one type of ultrasound device. The main aim of the study was to investigate the association between PD and SN hyperechogenicity measured by sonographic machine, not assessed so far. Materials and methods: In this study cross-sectional study SN hyperechogenicity was evaluated in 102 PD patients and 95 control subjects. Midbrain was visualised by Aloka Prosound 7 ultrasound device. SN area measurement, the relation to the clinical features of PD, inter- and intra-observer reliability were evaluated. Results: We confirmed that SN echogenicity is significantly increased in PD patients compared to control subjects (p < 0.001). The area under curve for PD patients vs. controls was 0.93. Receiver operating characteristic analysis indicated a cut-offs for SN echogenicity at 0.19 cm² with accuracy equal to 90%, specificity — 86% and sensitivity — 93.7%. The SN hyperechogenicity was not related to PD clinical findings. Reliability was good if an experienced sonographer performed the SN measurements. Conclusions: This study shows that the SN abnormality observed by TCS is a specific feature, which can be helpful in the process of PD diagnosing. (Folia Morphol 2014; 73, 3: 267–271)

• Wydawca: -
• Czasopismo: Folia Morphologica
• Rocznik: 2014
• Tom: 73
• Numer: 3
• Opis fizyczny: p.267-271,fig.,ref.

Twórcy

autor

Ambrosius W.

• Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland

autor

Michalak S.

• Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland

autor

Owecki M.

• Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland

autor

Lukasik M.

• Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland

autor

Florczak-Wyspianska J.

• Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland

autor

Kozubski W.

• Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland

Bibliografia

• 1. Ambrosius W, Kozubski W (2010) Transcranial sonography in diagnosis of movement disorders. Neurol Neurochir Pol, 44: 574–579.
• 2. Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K (1995) Degeneration of substantia nigra in chronic Parkinson’s disease visualized by transcranial color-coded real-time sonography. Neurology, 45: 182–184.
• 3. Behnke S, Runkel A, Kassar AS, Ortmann M, Guidez D, Dillmann U, Fassbender K, Spiegel J (2013) Long-term course of substantia nigra hyperechogenicity in Parkinson’s disease. Mov Disord, 28: 455–459.
• 4. Berg D, Becker G, Zeiler B, Tucha O, Hofmann E, Preier M, Benz P, Jost W, Reiners K, Lange KW (1999) Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology, 53: 1026–1031.
• 5. Berg D, Godau J, Riederer P, Gerlach M, Arzberger T (2010) Microglia activation is related to substantia nigra echogenicity. J Neural Transm, 117: 1287–1292.
• 6. Berg D, Godau J, Walter U (2008) Transcranial sonography in movement disorders. Lancet Neurol, 7: 1044–1055.
• 7. Berg D, Grote C, Rausch WD, Maeurer M, Wesemann W, Riederer P, Becker G (1999) Iron accumulation in the substantia nigra in rats visualized by ultrasound. Ultrasound Med Biol, 25: 901–904.
• 8. Berg D, Merz B, Reiners K, Naumann M, Becker G (2005) Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson’s disease. Mov Disord, 20: 383–385.
• 9. Berg D, Roggendorf W, Schröder U, Klein R, Tatschner T, Benz P, Tucha O, Preier M, Lange KW, Reiners K, Gerlach M, Becke G (2002) Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol, 59: 999–1005.
• 10. Berg D, Seppi K, Behnke S, Liepelt I, Schweitzer K, Stockner H, Wollenweber F, Gaenslen A, Mahlknecht P, Spiegel J, Godau J, Huber H, Srulijes K, Kiechl S, Bentele M, Gasperi A, Schubert T, Hiry T, Probst M, Schneider V, Klenk J, Sawires M, Willeit J, Maetzler W, Fassbender K, Gasser T, Poewe W (2011) Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. Arch Neurol, 68: 932–937.
• 11. Berg D, Siefker C, Becker G (2001) Echogenicity of the substantia nigra in Parkinson’s disease and its relation to clinical findings. J Neurol, 248: 684–689.
• 12. Brüggemann N, Hagenah J, Stanley K, Klein Ch, Wang C, Raymond D, Ozelius L, Bressman S, Saunders-Pullman R (2011) Substantia nigra hyperechogenicity with LRRK2 G2019S mutations. Mov Disord, 26: 885–888.
• 13. Campenhausen S, Bornschein B, Wick R, Bötzel K, Sampaio C, Poewe W, Oertel W, Siebert U, Berger K, Dodel R (2005) Prevalence and incidence of Parkinson’s disease in Europe. Eur Neuropsychopharmacol, 15: 473–490.
• 14. Doepp F, Plotkin M, Siegel L, Kivi A, Gruber D, Lobsien E, Kupsch A, Schreiber SJ (2008) Brain parenchyma sonography and 123I-FP-CIT SPECT in Parkinson’s disease and essential tremor. Mov Disord, 23: 405–410.
• 15. Elbaz A, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca W (2002) Risk tables for parkinsonism and Parkinson’s disease. J Clin Epidemiol, 55: 25–31.
• 16. Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol, 56: 33–39.
• 17. Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow W, Rascol O, Schrag A, Teresi JA, Van Hilten JJ, LaPelle N (2007) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord, 22: 41–47.
• 18. Hagenah JM, König IR, Becker B, Hilker R, Kasten M, Hedrich K, Pramstaller PP, Klein C, Seidel G. (2007) Substantia nigra hyperechogenicity correlates with clinical status and number of Parkin mutated alleles. J Neurol, 254: 1407–1013.
• 19. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression, and mortality. Neurology, 17: 427–442.
• 20. Huang YW, Jeng JS, Tsai CF, Chen LL, Wu RM (2007) Transcranial imaging of substantia nigra hyperechogenicity in a Taiwanese cohort of Parkinson’s disease. Mov Disord, 22: 550–555.
• 21. Kolevski G, Petrov I, Petrova V (2007) Transcranial sonography in the evaluation of Parkinson disease. J Ultrasound Med, 26: 509–512.
• 22. Korchounov A, Schipper HI, Preobrazhenskaya IS, Kessler KR, Yakhno NN (2004) Differences in age at onset and familial aggregation between clinical types of idiopathic Parkinson’s disease. Mov Disord, 19: 1059–1064.
• 23. Lo RY, Tanner CM (2013) Epidemiology. In: Pahwa R, Lyons KE eds. Handbook of Parkinson’s disease. 5 Ed. CRC Press, London, pp. 24–39.
• 24. Prestel J, Schweitzer KJ, Hofer A, Gasser T, Berg D (2006) Predictive value of transcranial sonography in the diagnosis of Parkinson’s disease. Mov Disord, 21: 1763–1765.
• 25. Ressner P, Skoloudík D, Hlustík P, Kanovský P (2007) Hyperechogenicity of the substantia nigra in Parkinson’s disease. J Neuroimaging, 17: 164–167.
• 26. Skoloudík D, Fadrná T, Bártová P, Langová K, Ressner P, Zapletalová O, Hlustík P, Herzig R, Kannovský P (2007) Reproducibility of sonographic measurement of the substantia nigra. Ultrasound Med Biol, 33: 1347–1352.
• 27. Van De Loo S, Walter U, Behnke S, Hagenah J, Lorenz M, Sitzer M, Hilker R, Berg D (2010) Reproducibility and diagnostic accuracy of substantia nigra sonography for the diagnosis of Parkinson’s disease. J Neurol Neurosurg Psychiatry, 81: 1087–1092.
• 28. Vlaar AM, De Nijs T, Van Kroonenburgh MJ. Mess WH, Winogrodzka A, Tromp SC, Weber WE (2008) The predictive value of transcranial duplex sonography for the clinical diagnosis in undiagnosed parkinsonian syndromes: comparison with SPECT scans. BMC Neurology, 8: 42.
• 29. Walter U (2012) Transcranial sonography of the cerebral parenchyma: Update on clinically relevant applications. Perspectives in Medicine, 1: 334–343.
• 30. Walter U, Behnke S, Eyding J, Niehaus L, Postert T, Seidel G, Berg D (2007) Transcranial brain parenchyma sonography in movement disorders: state of the art. Ultrasound Med Biol, 33: 15–25.
• 31. Walter U, Dressler D, Wolters A, Wittstock M, Benecke R (2007) Transcranial brain sonography findings in clinical subgroups of idiopathic Parkinson’s disease. Mov Disord, 22: 48–54.
• 32. Walter U, Wittstock M, Benecke R,Dressler D (2002) Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson’s disease. J Neural Transm, 192: 191–196.

Identyfikatory

DOI

10.5603/FM.2014.0042